PMC

Kaplan-Meier curves of survival by CD4 count by time since HAART initiation. Note that the scale of the y-axis starts at 0.75 for readability.

Kaplan Meier estimates of time to first change of any kind to initial HAART regimen, separated by gender Male or Female.

Kaplan Meier estimates of first line regimen substitutions during first 4 years of HAART. AZT, zidovudine; NVP, nevirapine; EFZ, efavirenz; d4T, stavudine.

Kaplan Meier estimates of time to initiation of second-line HAART Regimen, separated by gender male or female. Majority of patients (87%) were switched to second line following documented virologic failure.

Kaplan-Meier curves of lost to follow-up by CD4 count by time since HAART initiation. Patients were categorized as lost to follow-up if more than three months late for a scheduled visit, and if the tracing team was unable to gain information. Note that the scale of the y-axis starts at 0.75 for readability.

Kaplan-Meier estimates of viral rebound among patients with initial viral suppression. Initial virologic success is defined as viral load ≤ 400 copies/ml within six months of HAART initiation. Viral rebound is defined as two consecutive (or one if no additional measurement was available) viral load measurements greater than 400 copies/ml, or one viral load greater than 5000 among patients with initial virologic success.